aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Moximed Inc. is dedicated to developing minimally invasive joint-sparing solutions for patients suffering from knee osteoarthritis. Their flagship product, the MISHA Knee System, is an implantable shock absorber designed to unload the knee, relieve pain, and improve function. This innovative approach allows for quick recovery times, enabling patients to resume normal activities within days. Moximed serves a global market, providing advanced healthcare solutions to improve the quality of life for individuals with knee OA.
Moximed has made significant strides in the field of orthopedic medical devices, particularly with the successful implementation of the MISHA Knee System. The company's impact is evident in its ability to offer a new treatment paradigm for managing knee osteoarthritis, which has benefited numerous patients worldwide. Through their pioneering technology and commitment to patient care, Moximed continues to lead advancements in minimally invasive orthopedic solutions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Medical Devices
Technology
HealthTech
Tags
SaaS, Medical Device
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Moximed founded?
Moximed was founded in 2006.
Where is Moximed’s headquarters located?
Moximed’s headquarters is located in Hayward, CA, US.
How many employees does Moximed have?
Moximed has 45 employees as of Feb 5, 2024.
How much has Moximed raised to-date?
As of July 05, 2023, Moximed has raised a total of $183.2M (USD) since Aug 16, 2022.
Add Comparison
Total Raised to Date
$183.2M
USD
Last Update Aug 16, 2022
Total Employees Over Time
45
As of Feb 2024
Moximed Address
26460 Corporate Ave
suite 100
Hayward,
California
94545
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts